Baylor College of Medicine

Trial of LU AF82422 in participants with multiple system atrophy

Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email pa-webteam@bcm.edu. MyChart is a ...
Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Nasdaq

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, ...
MedCity News

Theravance Drug Fails Another Pivotal Test, This Time Sparking Restructuring That Ends R&D

An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
Insider Monkey

Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ...
KXAN

Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy

YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...
Yahoo Finance

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented at the 2026 AD/PD™ Conference Data evaluated safety, tolerability, ...
Nature

Clinical and neuroimaging correlates of disease related gait patterns in patients with multiple system atrophy cerebellar type

Multiple system atrophy (MSA) is a neurodegenerative disease characterized by cerebellar ataxia, parkinsonism, and autonomic dysfunction 1. Patients with MSA experience rapid disease progression, ...
Nature

Brain structural features with functional priori to classify Parkinson’s disease and multiple system atrophy using diagnostic MRI

Clinical two-dimensional (2D) MRI data has seen limited application in the early diagnosis of Parkinson’s disease (PD) and multiple system atrophy (MSA) due to quality limitations, yet its diagnostic ...
Medscape

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulin

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.
Business Wire

Inflammasome Therapeutics Announces Topline 3-month Data from a Clinical Trial of its First-in-Class Dual Inflammasome Inhibitor, K8, in Geographic Atrophy, Demonstrating Rapid ...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com/), a clinical-stage biotech company developing novel, first-in-class dual ...